A

ACELYRIN Inc
NASDAQ:SLRN

Watchlist Manager
ACELYRIN Inc
NASDAQ:SLRN
Watchlist
Price: 2.27 USD
Market Cap: $229.2m

Net Margin

0%
Current
No historical data
Comparison unavailable

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
$0
/
$0

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
$0
/
$0

Peer Comparison

Country Company Market Cap Net
Margin
US
ACELYRIN Inc
NASDAQ:SLRN
229.1m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
388.9B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
183.6B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
174.9B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.4B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.6B USD
Loading...
AU
CSL Ltd
ASX:CSL
88.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.7B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Not Available
No Country distribution data available for this multiple

ACELYRIN Inc
Glance View

Market Cap
229.2m USD
Industry
Biotechnology

ACELYRIN Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Agoura Hills, California and currently employs 51 full-time employees. The company went IPO on 2023-05-05. ACELYRIN, INC. is a late-stage clinical biopharmaceutical company. The firm is focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. Its initial focus is on the treatment of diseases with pathology related to excess activation of the immune system. The Company’s lead product candidate is izokibep, a small protein therapeutic designed to inhibit anti-interleukin (IL)-17A with high potency through tight binding affinity and the potential for robust tissue penetration due to its small molecular size, about one-tenth the size of a monoclonal antibody. The company is also advancing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against the insulin-like growth factor 1 receptor (IGF-1R). Lonigutamab has shown high potency against IGF-1R in both binding and functional laboratory assays. In addition, the Company is developing SLRN-517, which is a fully human IgG1 monoclonal antibody targeting c-KIT.

SLRN Intrinsic Value
4.44 USD
Undervaluation 49%
Intrinsic Value
Price
A
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Back to Top